1-10 of 10
Osama E. Rahma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

Lestat R. Ali, Patrick J. Lenehan, Victoire Cardot-Ruffino, Andressa Dias Costa, Matthew H.G. Katz, Todd W. Bauer, Jonathan A. Nowak, Brian M. Wolpin, Thomas A. Abrams, Anuj Patel, Thomas E. Clancy, Jiping Wang, Joseph D. Mancias, Matthew J. Reilley, Chee-Chee H. Stucky, Tanios S. Bekaii-Saab, Rawad Elias, Nipun Merchant, Craig L. Slingluff, Jr, Osama E. Rahma, Stephanie K. Dougan
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 542–553.
https://doi.org/10.1158/1078-0432.CCR-23-1444
Published: 01 February 2024
View article titled, PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
Open the PDF for PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T. Gibney, Howard A. Burris, Scott S. Tykodi, Osama E. Rahma, Tanguy Y. Seiwert, Kyriakos P. Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hashambhoy-Ramsay, Lara McGrath, Ellen Hooper, Xiaoying Xiao, Heather Cohen, Martin Fan, Daniel Felitsky, Courtney Hart, Rachel McComb, Karen Brown, Ali Sepahi, Judith Jimenez, Weidong Zhang, Johan Baeck, Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J. Harvey
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3695–3708.
https://doi.org/10.1158/1078-0432.CCR-21-4256
Published: 01 September 2022
View article titled, First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
Open the PDF for First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response in another window
Includes: Supplementary data
Journal Articles

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy

Xue Bai, Jiani Hu, Allison Betof Warner, Henry T. Quach, Christopher G. Cann, Michael Z. Zhang, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Lalit Pallan, Catriona Harvey, Michael P. Manos, Olivia Ouyang, Michelle S. Kim, Gyulnara Kasumova, Justine V. Cohen, Donald P. Lawrence, Christine Freedman, Riley M. Fadden, Krista M. Rubin, Tatyana Sharova, Dennie T. Frederick, Keith T. Flaherty, Osama E. Rahma, Georgina V. Long, Alexander M. Menzies, Jun Guo, Alexander N. Shoushtari, Douglas B. Johnson, Ryan J. Sullivan, Genevieve M. Boland
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5993–6000.
https://doi.org/10.1158/1078-0432.CCR-21-1283
Published: 01 November 2021
View article titled, Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy
Open the PDF for Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy in another window
Includes: Supplementary data
Journal Articles

Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbour, Olatunji B. Alese, Osama E. Rahma, James M. Cleary, Elad Sharon, Harvey J. Mamon, May Cho, Howard Streicher, Helen X. Chen, Mansoor M. Ahmed, Adrian Mariño-Enríquez, Seunghee Kim-Schulze, Sacha Gnjatic, Emanual Maverakis, Alina I. Marusina, Alexander A. Merleev, Mariano Severgnini, Kathleen L. Pfaff, James Lindsay, Jason L. Weirather, Srinika Ranasinghe, Alexander Spektor, Scott J. Rodig, F. Stephen Hodi, Jonathan D. Schoenfeld
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4940.
https://doi.org/10.1158/1078-0432.CCR-21-2698
Published: 01 September 2021
View article titled, Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
Open the PDF for Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer in another window
Journal Articles

A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbour, Olatunji B. Alese, Osama E. Rahma, James M. Cleary, Elad Sharon, Harvey J. Mamon, May Cho, Howard Streicher, Helen X. Chen, Mansoor M. Ahmed, Adrian Mariño-Enríquez, Seunghee Kim-Schulze, Sacha Gnjatic, Emanual Maverakis, Alina I. Marusina, Alexander A. Merleev, Mariano Severgnini, Kathleen L. Pfaff, James Lindsay, Jason L. Weirather, Srinika Ranasinghe, Alexander Spektor, Scott J. Rodig, F. Stephen Hodi, Jonathan D. Schoenfeld
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2470–2480.
https://doi.org/10.1158/1078-0432.CCR-20-4632
Published: 01 May 2021
View article titled, A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
Open the PDF for A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors

Osama E. Rahma, Joshua E. Reuss, Anita Giobbie-Hurder, Ghazaleh Shoja E Razavi, Osama Abu-Shawer, Pooja Mehra, Seema Gupta, Richard Simon, Samir N. Khleif
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 485–491.
https://doi.org/10.1158/1078-0432.CCR-20-2669
Published: 19 January 2021
View article titled, Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors
Open the PDF for Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)

Aljosja Rogiers, Carlo Tondini, Joe M. Grimes, Megan H. Trager, Sharon Nahm, Leyre Zubiri, Neha Papneja, Arielle Elkrief, Jessica Borgers, April Rose, Johanna Mangana, Michael Erdmann, Ines Pires da Silva, Christian Posch, Axel Hauschild, Lisa Zimmer, Paola Queirolo, Caroline Robert, Karijn Suijkerbuijk, Paolo A. Ascierto, Paul Lorigan, Richard Carvajal, Osama E Rahma, Mario Mandala, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): S02-01.
https://doi.org/10.1158/1557-3265.COVID-19-S02-01
Published: 15 September 2020
View article titled, Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)
Journal Articles

The Intersection between Tumor Angiogenesis and Immune Suppression

Osama E. Rahma, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5449–5457.
https://doi.org/10.1158/1078-0432.CCR-18-1543
Published: 13 September 2019
View article titled, The Intersection between Tumor Angiogenesis and Immune Suppression
Open the PDF for The Intersection between Tumor Angiogenesis and Immune Suppression in another window
Journal Articles

Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma

Austin G. Duffy, Chi Ma, Susanna V. Ulahannan, Osama E. Rahma, Oxana Makarova-Rusher, Liang Cao, Yunkai Yu, David E. Kleiner, Jane Trepel, Min-Jung Lee, Yusuke Tomita, Seth M. Steinberg, Theo Heller, Baris Turkbey, Peter L. Choyke, Cody J. Peer, William D. Figg, Brad J. Wood, Tim F. Greten
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (16): 4633–4641.
https://doi.org/10.1158/1078-0432.CCR-16-3171
Published: 14 August 2017
View article titled, Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma
Open the PDF for Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Is the “3+3” Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design

Osama E. Rahma, Emily Gammoh, Richard M. Simon, Samir N. Khleif
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (18): 4758–4767.
https://doi.org/10.1158/1078-0432.CCR-13-2671
Published: 14 September 2014
View article titled, Is the “3+3” Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design
Open the PDF for Is the “3+3” Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design in another window
Includes: Supplementary data